An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer.

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2012
This article has no abstract
Epistemonikos ID: 3202c08792c8d3c0378320ed51a62f3cedbd599f
First added on: Feb 05, 2025